CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Velcade for Multiple Myeloma - Details

Project Number PC0016-000
Brand Name Velcade
Generic Name Bortezomib
Strength 3.5mg/vial
Tumour Type Myeloma
Indication Multiple Myeloma
Funding Request For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Janssen
Sponsor Cancer Care Ontario Hematology Disease Site Group
Submission Date October 29, 2012
Submission Deemed Complete November 5, 2012
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ November 13, 2012
Check-point meeting December 18, 2012
pERC Meeting February 21, 2013
Initial Recommendation Issued March 7, 2013
Feedback Deadline ‡ March 21, 2013
Final Recommendation Issued March 25, 2013
Notification to Implement Issued April 11, 2013
Therapeutic Area Multiple Myeloma
Recommendation Type Reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.